In Response

Bradley H Lee^{1

2}, Alexandra Sideris^{1

3}

Affiliations

¹ Department of Anesthesiology, Critical Care & Pain Management, Hospital for Special Surgery, New York, New York.
² Department of Anesthesiology, Weill Cornell Medicine, New York, New York, leeb@hss.edu.
³ Department of Anesthesiology, Weill Cornell Medicine, New York, New York.

Bradley H Lee et al. Anesth Analg. 2024.

. 2024 Jun 1;138(6):e39-e40.

doi: 10.1213/ANE.0000000000006983. Epub 2024 May 20.

Bradley H Lee^{1

2}, Alexandra Sideris^{1

3}

¹ Department of Anesthesiology, Critical Care & Pain Management, Hospital for Special Surgery, New York, New York.
² Department of Anesthesiology, Weill Cornell Medicine, New York, New York, leeb@hss.edu.
³ Department of Anesthesiology, Weill Cornell Medicine, New York, New York.

No abstract available

References

1. Horvath B, Saadat H, Kloesel B. Cannabis hyperemesis syndrome: perioperative concern with potential paradoxical response to propofol. Anesth Analg. 2024;138:e38–e39.
1. Gajendran M, Sifuentes J, Bashashati M, McCallum R. Cannabinoid hyperemesis syndrome: definition. J Investig Med. 2020;68:1309–1316.
1. Sun HJ, Lu Y, Wang HW, et al. Activation of endocannabinoid receptor 2 as a mechanism of propofol pretreatment-induced cardioprotection against ischemia-reperfusion injury in rats. Oxid Med Cell Longev. 2017;2017:2186383.
1. Parekh JD, Wozniak SE, Kham K, et al. Cannabinoid hyperemesis syndrome. BMJ Case Rep. 2016;0:2016.
1. Ruberto AJ, Sivilotti MLA, Forrester S, Hall AK, Crawford FM, Day AG. Intravenous haloperidol versus ondansetron for cannabis hyperemesis syndrome (HaVOC): a randomized, controlled trial. Ann Emerg Med. 2021;77:613–619.